Literature DB >> 3820226

Selective cytotoxicity of a system L specific amino acid nitrogen mustard.

D R Haines, R W Fuller, S Ahmad, D T Vistica, V E Marquez.   

Abstract

The synthesis and characterization of DL-2-amino-7-bis[(2-chloroethyl)amino]-1,2,3,4-tetrahydro-2-naphthoic acid and DL-2-amino-5-bis[(2-chloroethyl)amino]-1,2,3,4-tetrahydro-2-napthoic+ ++ acid were accomplished. The correct assignment of the site of attachment of the bis(2-chloroethyl)amino side chain was ascertained by selective proton decoupling of the 13C NMR spectra performed on the corresponding nitrospirohydantoin precursors 2 and 3, which were obtained from the nitration of beta-tetralone hydantoin. The two target compounds 6 and 7 were designed as tumor-specific agents capable of being selectively transported into tumor cells by the leucine-preferring transport system (system L). Inhibition analysis of the initial rate of transport of the system L specific substrate 2-amino-bicyclo[2.2.1]heptane-2-carboxylic acid (BCH) by 6 and 7 indicated that the 7-substituted isomer 6 was an extremely potent competitive inhibitor of that transport system in murine L1210 leukemic cells (Ki = 0.2 microM). Evaluation of the selectivity of this compound indicated that it possessed enhanced in vitro antitumor activity and reduced myelosuppressive activity when compared to its prototype amino acid nitrogen mustard, L-phenylalanine mustard (L-PAM). In addition to being more selectively toxic to tumor cells, this compound differs from L-PAM in having a 2-3-fold shorter half-life (t1/2).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3820226     DOI: 10.1021/jm00386a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.

Authors:  Jyothi Matharu; Jun Oki; David R Worthen; Quentin R Smith; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-24       Impact factor: 2.823

2.  Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.

Authors:  Y Takada; N H Greig; D T Vistica; S I Rapoport; Q R Smith
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches.

Authors:  Anastazja Poczta; Aneta Rogalska; Agnieszka Marczak
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

4.  Mechanism of substrate transport and inhibition of the human LAT1-4F2hc amino acid transporter.

Authors:  Renhong Yan; Yaning Li; Jennifer Müller; Yuanyuan Zhang; Simon Singer; Lu Xia; Xinyue Zhong; Jürg Gertsch; Karl-Heinz Altmann; Qiang Zhou
Journal:  Cell Discov       Date:  2021-03-23       Impact factor: 10.849

Review 5.  Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.

Authors:  Natesh Singh; Gerhard F Ecker
Journal:  Int J Mol Sci       Date:  2018-04-24       Impact factor: 5.923

Review 6.  L-Type amino acid transporter 1 as a target for drug delivery.

Authors:  Elena Puris; Mikko Gynther; Seppo Auriola; Kristiina M Huttunen
Journal:  Pharm Res       Date:  2020-05-06       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.